These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 22574672

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fibroblast growth factor 23 and the future of phosphorus management.
    Wolf M.
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):463-8. PubMed ID: 19770756
    [Abstract] [Full Text] [Related]

  • 5. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM.
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality.
    Block GA.
    Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):376-81. PubMed ID: 21519253
    [Abstract] [Full Text] [Related]

  • 8. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community.
    Larsson TE, Olauson H, Hagström E, Ingelsson E, Arnlöv J, Lind L, Sundström J.
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):333-9. PubMed ID: 19948843
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Fibroblast growth factor 23 and the heart.
    Faul C.
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):369-75. PubMed ID: 22531163
    [Abstract] [Full Text] [Related]

  • 12. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C, IMPROVE-CKD Writing Committee..
    BMJ Open; 2019 Feb 21; 9(2):e024382. PubMed ID: 30796122
    [Abstract] [Full Text] [Related]

  • 13. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL, Swan VJ, Jamal SA.
    Clin J Am Soc Nephrol; 2010 Jan 21; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [Abstract] [Full Text] [Related]

  • 14. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA, Stephens BW.
    Adv Chronic Kidney Dis; 2011 Mar 21; 18(2):120-31. PubMed ID: 21406297
    [Abstract] [Full Text] [Related]

  • 15. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I, Haffner D, Leifheit-Nestler M.
    Toxins (Basel); 2019 Nov 06; 11(11):. PubMed ID: 31698866
    [Abstract] [Full Text] [Related]

  • 16. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
    Heine GH, Seiler S, Fliser D.
    Nephrol Dial Transplant; 2012 Aug 06; 27(8):3072-81. PubMed ID: 22851630
    [Abstract] [Full Text] [Related]

  • 17. [Pathogenesis and treatment of vascular calcification in CKD].
    Brancaccio D, Gallieni M, Pasho S, Fallabrino G, Olivi L, Volpi E, Ciceri P, Missaglia E, Ronga C, Brambilla C, Butti A, Rocca-Rey L, Chiarelli G, Cozzolino M.
    G Ital Nefrol; 2009 Aug 06; 26 Suppl 45():S20-7. PubMed ID: 19382090
    [Abstract] [Full Text] [Related]

  • 18. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?
    Covic A, Voroneanu L, Goldsmith D.
    Nephron Clin Pract; 2010 Aug 06; 116(3):c187-95. PubMed ID: 20606478
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast growth factor 23 and the bone-vascular axis: lessons learned from animal studies.
    Zoppellaro G, Faggin E, Puato M, Pauletto P, Rattazzi M.
    Am J Kidney Dis; 2012 Jan 06; 59(1):135-44. PubMed ID: 22070851
    [Abstract] [Full Text] [Related]

  • 20. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F.
    G Ital Nefrol; 2010 Jan 06; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.